Staphylococcus aureus is the pathogen responsible for the majority of human skin infections. In particular, the methicillin-resistant variety, MRSA, has become a global clinical concern. The extensive use of mupirocin, the first-line topical antibacterial drug of choice, has led to the emergence of mupirocin-resistant MRSA globally, resulting in the urgent need for a replacement. Antimicrobial peptides are deemed plausible candidates. Herein, we describe a structure-activity relationship approach in the design of an ultra-short peptide with potent anti-MRSA activity with a rapid, bactericidal mode of action. Coupled to a low cytotoxic activity, we believe our lead compound can be developed into a topical antibacterial agent to replace mupirocin as the first-line drug for treating MRSA skin infections.
| INTRODUCTION
Staphylococcus aureus is a gram-positive bacteria primarily responsible for human skin and soft tissue infections. [1] [2] [3] Of particular clinical concern are the methicillin-resistant strains known as methicillin-resistant S. aureus (MRSA), prompting the American Centers for Disease Control and Prevention to flag them as a "serious threat" in their 2013 antibiotic resistance threat report. [4] Mupirocin, the first-line topical drug of choice, has been in use since 1985. [5] This has inevitably led to the global emergence of mupirocin-resistant MRSA through selective pressure and cross-transmission. [5] [6] [7] [8] [9] [10] [11] [12] For example, a Swiss hospital study revealed mupirocin-resistant MRSA clinical isolates increased from 0% to 80% between 1999 and 2008, [13] resulting in the urgent need for the development of new topical antibacterials. [14, 15] Antimicrobial peptides (AMPs) are deemed a promising class of antibacterial agents due to their rapid bactericidal activities as they directly target and disrupt bacterial cell membranes. [16] [17] [18] Their rapid mechanism of action can significantly reduce the probability of resistance development compared to traditional antibiotics which target bacterial cellwall components, proteins, or enzymes. [16] [17] [18] However, two major impediments in developing peptides into drugs are their lack of oral bioavailability and high manufacturing cost. [18] [19] [20] The first hurdle can be circumvented by developing peptide drugs for topical applications. For example, a 12-residue tryptophan-rich AMP, omiganan, entered phase 2 clinical trials in 2015 as a topical antibacterial agent for the treatment of acne vulgaris (ClinicalTrials.gov identifier: NCT02571998).
To address the second hurdle, the manufacturing cost can be minimized by identifying and selecting very short peptides with potent antibacterial activities for development. Toward this goal, we conducted a head-to-head anti-MRSA activity comparison on 30 short peptides up to nine residues in length that were reported in the literature. [21] Experimental results revealed that nonapeptide P9-4 (KWRRWIRWL-NH 2 ) possessed the most potent activity against hospital-acquired, mupirocin-susceptible MRSA (ATCC-BAA-1681) with a minimum inhibitory concentration (MIC) of 3.125 μm.
P9-4 is a rationally designed, tryptophan-rich synthetic peptide developed by Qi and coworkers from a hit peptide identified from a synthetic peptide library. [22] P9-4 was also found to have very low hemolytic activity toward human erythrocytes (HC 50 400 μg/ml), suggesting that it can potentially be developed as an antibacterial drug. [22] In this paper, we describe our efforts to enhance the potency of P9-4 against mupirocin-resistant MRSA via a structure-activity relationship (SAR) study while retaining its low hemolytic property. At the same time, we sought to reduce manufacturing cost by peptide truncation and the replacement of expensive arginine residues with cheaper amino acids. The novel lead peptide was then screened against a panel of clinical MRSA isolates, followed by a bactericidal/ static determination assay, a time-kill assay, and a human epidermal keratinocyte viability assay to gauge its potential for development as a topical antibacterial to replace mupirocin for the treatment of MRSA skin infections.
| METHODS AND MATERIALS

| Peptide synthesis, antibiotics, chemicals, and bacteria
All peptides were synthesized and purified to >95% purity commercially by GL Biochem (China). Mupirocin calcium and propylene glycol were purchased from Sigma-Aldrich (USA). MRSA were purchased from ATCC (USA).
| Minimum inhibitory concentration (MIC) assay
The MICs of test compounds were determined using the broth microdilution protocol from the Clinical and Laboratory Standards Institute guidelines. [23] Briefly, bacteria were grown fresh from frozen stock on Mueller Hinton 2 (MH2) agar at 37°C. After overnight incubation, five colonies were selected to grow in cation-adjusted MH2 broth in a shaking incubator (220 RPM) at 37°C. Cells were grown to an optical density (OD 600 ) of 0.13-0.17 determined using a spectrophotometer (Molecular Devices Spectra Max Plus), which corresponds to ~1 × 10 8 CFU/ml. Test compounds were constituted into 4 mm DMSO stock solutions and then subjected to twofold serial dilution in a 96-well plate with concentrations ranging from 100 to 0.195 μm in duplicates. 50 μl of microbial culture containing ~1 × 10 6 CFU/ml of microbes in the respective broths was introduced into each well containing 50 μl of compound solution. After an overnight incubation at 35°C, OD 600 measurements were conducted using the microplate spectrophotometer. MIC was defined as the lowest test compound concentration (μm) required to inhibit visible microbial growth.
| Bactericidal/static determination assay
After the MICs of the test compounds were determined using the microdilution method described earlier on, the entire content of the well (100 μl) corresponding to 1×, 2×, and 4× MIC of the test compounds was transferred and spread on sterile MH2 agar plates and incubated overnight at 37°C. The number of colony-forming units (CFU) was counted the next day. A test compound was classified as bactericidal if <0.1% of the original inoculum was observed on the plate.
| Time-kill assay
Bacterial cells were grown to 1 × 10 8 CFU/ml in MH2 broth and then diluted 200-fold into 5 ml aliquots to a density of 5 × 10 5 CFU/ml in a flask. Test compounds predissolved in DMSO corresponding to 4× their MICs were then added into each flask with a final DMSO concentration of 2.5% v/v. The negative control was 2.5% DMSO. The flasks were incubated in a shaking incubator (220 RPM) at 37°C. Samples (100 μl) were taken between t = 0, 0.25, 0.5, 1, 2, 3, 4, 5, and 6 hr. The samples were serially diluted in MH2 broth before plating on MH2 agar and incubated overnight at 37°C. A bacteria count for each plate was conducted the next day. The Log CFU/mL was plotted against time to obtain a time-kill graph using GraphPad Prism software.
| Human epidermal keratinocyte viability assay
Normal human epidermal keratinocytes (NHEK) were purchased from Lonza (catalog #00192627) and cultured in keratinocyte growth medium (Lonza KGM-Gold BulletKit) containing growth supplements (Lonza Reagent Pack) at 5% CO 2 (37°C). The cell viability assay was performed using the CellTiter-Glo Luminescent Cell Viability Assay protocol from Promega (www.promega.com). Briefly, NHEK were treated with test compounds in keratinocyte growth medium in 96-well plates (Thermo Scientific Nunclon Delta). Treated cells were incubated for 5 days at 5% CO 2 (37°C). Promega CellTiter-Glo Reagent was added, and plates were shaken on an orbital shaker for 2 hr. Next, well contents (100 μl) from each well were transferred into opaque 96-well plates (PerkinElmer OptiPlate-96) and luminescence measured by a microplate reader (Tecan Safire 2).
| RESULTS AND DISCUSSION
The MICs of clinical AMP candidate Omiganan and P9-4 against mupirocin-resistant MRSA (ATCC-BAA-1556) are summarized in Table 1 . The FDA-approved first-line antibacterial drug mupirocin was included for comparison. Omiganan was found to be active against mupirocinresistant MRSA with an MIC of 12.5 μm, in agreement with the reported MIC range of 16-32 μg/ml (8-16 μm) against 31 MRSA strains. [24] Interestingly, the 9-residue P9-4 displayed an MIC of 6.25 μm (Table 1) , twofold more active than 12-residue omiganan, suggesting that with proper design, shorter peptides can be made more potent than omiganan. As expected, mupirocin was found to be impotent against mupirocin-resistant MRSA (MIC > 100 μm).
T A B L E 1 MICs (μm) of various drugs and peptides against mupirocin-resistant MRSA (ATCC-BAA-1556)
To further probe the effects of peptide length versus bioactivity, we truncated P9-4 from the N-and C-termini to see whether the shortened analogs remained MRSA-active (peptides 1 to 8; Table 1 ). MIC data revealed that just a single amino acid removal from either the N-or C-terminus resulted in two-to fourfold bioactivity reduction (peptides 1 and 5; Table 1 ). Further truncation resulted in total bioactivity loss (MICs > 100 μm; Table 1 ), suggesting that a minimum peptide length of nine residues was required for potent (singledigit micromolar) activity against MRSA. An advantage of designing short peptides over long ones is that the former tend to possess less cytotoxic effects against human cells.
Next, an alanine scan was conducted to elucidate which amino acid residues were crucial for antibacterial activity (peptides 9 to 17; Table 1 ). MIC results revealed every amino acid residue in P9-4 was important because a single alanine mutation resulted in 2-to fourfold bioactivity loss (MICs 12.5 to 25 μm; Table 1 ). Particularly important were tryptophan W2, W5, and W8 where alanine substitution resulted in a fourfold activity reduction (peptides 10, 13, and 16; MICs 25 μm). This was not surprising as tryptophan's indole side chain has been shown to possess a high affinity for a phospholipid's carbonyl (C=O) moiety and the ability to disrupt the cohesive hydrophobic interactions between lipids in a phospholipid bilayer and thus imbibing tryptophan-rich peptides with membrane-disrupting properties. [25] [26] [27] [28] [29] [30] Indeed, tryptophan residues constituted a third of the residues found in omiganan and P9-4 (4 of 12 and 3 of 9, respectively) which serves to explain their ability to lyse bacterial membranes. [22, 31] The alanine scan also indicated that the positively charged residues K1, R3, R4, and R7 played important antibacterial activity roles as a single alanine substitution caused a twofold potency reduction (peptides 9, 11, 12, and 15; MICs 12.5 μm; Table 1 ). Cationic residues are crucial for antibacterial properties due to the anionic nature of bacterial membranes caused by the prevalence of negatively charged teichoic acids and phospholipids. [31] [32] [33] The electrostatic attraction formed between the anionic membrane and the cationic arginine or lysine residues of P9-4 facilitates peptide-membrane binding followed by membrane insertion and subsequent disruption. [22] Interestingly, substituting the aliphatic hydrophobic I6 and L9 with alanine also resulted in a twofold activity reduction, suggesting that aliphatic side chains also played an important role (peptides 14 and 17; MICs 12.5 μm; Table 1 ). Indeed, the aliphatic leucine side chains in AMPs have been observed to insert into model phospholipid membranes [34] while another study showed that leucine increases the propensity of peptides to form amphiphilic helices in solution, a structural requirement for antibacterial activity. [35] Based on this, we decided to conduct a leucine scan to identify which residue can be replaced with leucine without bioactivity loss. This serves to reduce peptide manufacturing cost as Fmoc-protected leucine is eight-and sixfold cheaper than Fmoc-protected arginine and tryptophan, respectively, based on prices in the Sigma-Aldrich website (www.sigmaaldrich. com). Leucine scanning revealed that the majority of leucinesubstituted analogs suffered bioactivity loss (peptides 18 to 25; Table 1 twofold (MIC 3.125 μm; Table 1 ). This may be due to isoleucine being more hydrophobic than leucine based on their hydropathy scores of 4.5 and 3.8, respectively. [36] From the leucine scan results, the most potent compound, peptide 23 (KWRRWLRWL-NH 2 ; MIC 3.125 μm), was selected for further SAR studies. In the next series of analogs, R3 was substituted for the cheaper leucine as this did not affect bioactivity (peptide 20; Table 1 ). We also decided to explore replacing residues K1 and R4. The rationale for replacing the sole lysine (K1) with either leucine or tryptophan was to lower manufacturing cost. We also wanted to see whether we could reduce the number of expensive arginine residues by substituting R4 with either leucine or tryptophan. Hence, the next four peptide analogs containing substituted K1 and R4 (26) (27) (28) (29) were synthesized. MIC results revealed that all four analogs were more potent than reference peptide P9-4, with tryptophan-rich peptide 29 (WWLWWLRWL-NH 2 ) displaying the highest potency against mupirocin-resistant MRSA (MIC 1.56 μm; Table 1 ), two-to fourfold more potent than peptides 23 and P9-4, respectively.
F I G U R E 1
Next, lead peptide 29 was subjected to further SAR studies. Sequence reversal resulted in an unexpected twofold activity reduction (peptide 30; LWRLWWLWW-NH 2 ; MIC 3.125 μm; Table 1 ). A possible reason for the observed MIC difference could be that the peptides' primary sequences may be playing a role in their abilities to disrupt bacterial membranes. Further studies involving molecular dynamic simulations of peptide-model membrane interaction may shed some light into this and is beyond the scope of this paper. Next, an attempt to further enhance peptide 29's antibacterial potency was made by attaching a palmitoyl (C16) fatty acid moiety to its N-terminus (peptide 31). This technique has been reported to enhance the antibacterial activities of some AMPs as the hydrophobic alkyl C16 chain facilitates peptide-membrane insertion and subsequent disruption. [37, 38] Strangely, our MIC results revealed lipopeptide 31 to be impotent (MIC > 100 μm; Table 1 ). We suspected that the peptide's positively charged N-terminal amine may be important for antibacterial activity and could have reduced lipopeptide 31's ability to bind to the anionic bacterial membrane. Unsurprisingly, N-terminal acetylated peptide 32 also displayed poor anti-MRSA activity (MIC 25 μm; Table 1 ), suggesting that the N-terminal-positive charge was important for antibacterial activity. To test this hypothesis further, peptide 33 with a negatively charged Cterminal carboxylate group also exhibited significant activity loss (WWLWWLRWL-OH; MIC 25 μm; Table 1) . From these results, we concluded that the minimum number of positive charges that a peptide must possess for antibacterial activity is +2. In an attempt to reduce manufacturing cost further, the sole arginine (R7) of lead peptide 29 was substituted with leucine and tryptophan (peptides 34-35, respectively; Table 1 ). MIC results revealed both peptides to be impotent (MICs > 100 μm; Table 1 ), supporting our earlier deductions that a peptide must possess a minimum two positive charges for antibacterial activity.
Intrigued by the lone arginine in peptide 29, we relocated it at various positions along the peptide chain (peptides 36-43; Table 1) . Surprisingly, experimental results revealed peptides with MICs ranging between 3.125 and 6.25 μm, none of which were more potent than lead peptide 29 (MIC 1.56 μm). This suggested that the position of the arginine in the peptide sequence played an important role in antibacterial activity.
Lastly, we truncated lead peptide 29 to see whether we could further reduce peptide length (peptides 44-47; Table 1 ). Unfortunately, MIC results revealed that a single residue removal, either at the N-or C-termini, resulted in a fourfold bioactivity reduction (peptides 44 and 46; MICs 6.25 μm; Table 1 ) and the removal of two residues caused eightfold bioactivity losses (peptides 45 and 47; MICs 12.5 μm; Table 1 ), indicating that the shortest peptide length required for potent anti-MRSA activity was nine residues.
From the SAR study involving peptides 1 to 47, peptide 29 was found to be the most potent against mupirocin-resistant MRSA (MIC 1.56 μm; Table 1 ). Compared to reference peptide P9-4, peptide 29 was fourfold more potent (MIC 1.56 vs. 6.25 μm). We suspect this was probably due to the increased number of membrane-active tryptophan residues in peptide 29 compared to P9-4 (five vs. three, respectively). Interestingly, the reduction in the number of cationic residues in peptide 29 compared to P9-4 (1 vs. 4, respectively) did not affect antibacterial potencies.
Peptide 29 was next tested against a panel of clinical MRSA strains with mupirocin and P9-4 as comparators ( Table 2) .
As expected, mupirocin was found to be inactive against mupirocin-resistant strains while displaying high activity against susceptible strains (MICs ≤ 0.39 μm; Table 2 ). Table 2 also revealed peptide 29 to be highly potent against all nine MRSA strains (MICs 1.56 μm; Table 2 ), up to fourfold more potent than P9-4 (MICs 3.125 to 6.25 μm; Table 2 ). This suggested peptide 29 has a high potential for further development as a topical antibacterial. Lead peptide 29 was subsequently subjected to a bactericidal/ static determination assay against mupirocin-resistant MRSA with P9-4 as a comparator (Figure 1) . A bactericidal drug is advantageous over a bacteriostatic one as the former can significantly reduce the chances of resistance development.
The bactericidal/static determination assay revealed both peptides to be bactericidal, with peptide 29 exhibiting a minimum bactericidal concentration (MBC) of 1.56 μm (1× MIC) while P9-4 possessed an MBC of 12.5 μm (2× MIC), suggesting that MRSA was more susceptible toward peptide 29 compared to P9-4.
Next, both peptides were subjected to a time-kill assay using mupirocin-resistant MRSA (Figure 2) . A compound with rapid-killing bactericidal activity is generally preferred as it can potentially reduce the chance of resistance development and treatment duration.
The time-kill graph ( Figure 2 ) revealed both peptides to be rapidly bactericidal, causing a 6-log reduction in bacteria count within one hour. This extremely rapid bactericidal mechanism suggested both peptides were acting via a membrane-lytic mechanism.
The membrane-disrupting nature of AMPs has raised concerns that they may be too cytotoxic to be used as drugs. For example, melittin, a 26-residue AMP isolated from bee venom, is extremely hemolytic toward human erythrocytes at low micromolar concentrations. [39] However, short cationic tryptophan-rich AMPs up to 10 residues in length have been reported to be noncytotoxic. [22, 29, [40] [41] [42] Hence, peptide 29 was subjected to a human epidermal keratinocyte viability assay with clinical candidate omiganan as comparison ( Figure 3 ). Propylene glycol, an FDA-approved solvent used in many topical creams, gels, and lotions, was used as a control. Experimental results revealed peptide 29 was relatively less cytotoxic than omiganan (GI 50 18.1 vs. 57.5 μm respectively; Figure 3) . Based on this, we believe that peptide 29 can be safely developed as a topical drug.
| CONCLUSIONS
By utilizing an SAR approach, we designed nonapeptide 29 with high potency against a range of clinical MRSA strains. Peptide 29 possessed a fourfold activity enhancement over reference synthetic AMP P9-4 and was found to be rapidly bactericidal with an MBC of 1.56 μm. Peptide 29 was also found to have low cytotoxicity, making it a potential candidate to replace mupirocin as the first-line topical antibacterial drug for treating skin infections.
